1. **Background:**
   Zytiga™ (abiraterone acetate) is a CPY17 inhibitor-indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.\(^1\)

2. **Coverage Information:**
   Members will be required to meet the criteria below for coverage. For members under the age of 19 years, the prescription will automatically process without a coverage review.

   Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances. Some states also mandate usage of other Compendium references. Where such mandates apply, they supersede language in the benefit document or in the notification criteria.

3. **Coverage Criteria:**

   **A. Patients less than 19 years of age**
   1. **Zytiga** will be approved based on the following criterion:
      a. Member is less than 19 years of age
   
      **Authorization will be issued for 12 months.**

   **B. Prostate Cancer**
   1. **Initial Authorization**
      a. **Zytiga** will be approved based on **both** of the following criteria:

         1. Diagnosis of metastatic castration-resistant or recurrent prostate cancer
         
            -AND-

         2. Used in combination with prednisone
Authorization will be issued for 12 months.

B. Reauthorization

1. Zytiga will be approved based on the following criterion:

   a. Patient does not show evidence of progressive disease while on Zytiga therapy

Authorization will be issued for 12 months.

3. Additional Clinical Rules:

   • Supply limits may be in place.

4. References:


<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization/Notification - Zytiga (abiraterone acetate)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Change Control</strong></td>
</tr>
<tr>
<td>11/2014</td>
<td>Annual review with no change to coverage. Updated references.</td>
</tr>
<tr>
<td>11/2015</td>
<td>Annual review. Minor revision to prostate cancer criteria.</td>
</tr>
<tr>
<td></td>
<td>Updated background &amp; references.</td>
</tr>
<tr>
<td>9/2016</td>
<td>Annual review. Updated references.</td>
</tr>
</tbody>
</table>